MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..

Atacand (candesartan cilexetil)

Company: Astra Merck
Approval Status: Approved June 1998
Treatment for: hypertension
Areas: Cardiovascular / Cardiology; Diabetes / Endocrinology
Possible similar drugs: Atacand; Atacand

| General Information | Clinical Results | Side Effects |

General Information

Astra Merck, Inc. announced it has received approval from the US Food and Drug Administration (FDA) to market Atacand (R) (candesartan cilexetil) for once-daily treatment of hypertension. Atacand belongs to a group of antihypertensive medications called angiotensin II receptor blockers (ARB) which represent the first new class of antihypertensive agents in the U.S. in more than a decade.

Clinical Results

In clinical trials involving more than 7000 hypertensive patients, Atacand has been shown to reduce blood pressure in a consistent and dose-dependent manner over a 24-hour period. In clinical trials, treatment with Atacand has been well tolerated with an adverse event rate similar to placebo.

Side Effects

Adverse experiences that occurred in at least one percent of patients treated with Atacand and at a higher incidence versus placebo included back pain, dizziness, upper respiratory tract infection, pharyngitis and rhinitis. Atacand should not be used in women who are pregnant or by people who are allergic to any component of the medication.

< back to top

Atacand Drug Information

The Atacand drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2016 All rights reserved.